Lipoprotein metabolism Flashcards

1
Q

Lipoproteins smallest to largest

A

Chylomicrons > VLDL > LDL > HDL (2 types - 2 > 3)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Process of cholesterol metabolism

A
  • Dietary cholesterol absorbed across jejenum brush border by NPC1L1 (note ABC G5 + G8 act in opposite direction). More cholesterol is absorbed downstream in the ileum, in the form of bile acids
  • Cholesterol goes to liver + down-regulates HMG-coA reductase that synthesises cholesterol de novo
  • Either used for bile acid synthesis or esterified by ACAT to form VLDL (LDL pre-cursor)
  • LDL can carry cholesterol to the peripheries (bad) or bind LDL receptors on the liver to place cholesterol back in the liver for excretion (better)
  • HDL carries cholesterol from peripheries to liver via ABCA1 at periphery + SRB1 at liver
  • Cholesterol returned to the liver can be excreted
  • CETP transfers cholesterol between LDL + HDL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Process of triglyceride metabolism

A
  • Dietary triglyceride absorbed in small intestine + assembled into chylomicrons
  • Chylomicrons hydrolysed by LPL enzyme (in skeletal muscle + adipose tissue capillaries) + free fatty acids released into blood
  • Free fatty acids used in liver to form VLDL or incorporated into adipose tissue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

VLDL composition

A

Cholesterol ester
Triglyceride
ApoB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Milky plasma due to excess chylomicrons in blood

A

LPL deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

4 types of dyslipidaemia

A

Hypercholesterolaemia (high cholesterol)
Hypertriglyceridaemia (high triglycerides)
Mixed hyperlipidaemia (high cholesterol + triglycerides)
Hypolipidaemia (low cholesterol + triglyceride)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Action of PCSK9 inhibitor

A

PCSK9 inhibitors lower circulating LDL levels
Circulating LDL is a key risk factor for atherosclerosis
PCSK9 binds and degrades LDL receptors on hepatocytes, which normally helpfully remove LDL from the circulation
PCSK9 inhibitors prevent LDL receptor degradation and reduce circulating LDL levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Main transporters of cholesterol

A

LDL (70%)

HDL (17%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Main transporters of triglycerides

A

VLDL

Chylomicrons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Two main lipids

A

Triglyceride

Cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Main carriers of dietary triglyceride absorbed from small intestine

A

Chylomicrons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

LDLR (or less commonly apoB / PCSK9 mutations)
Monogenic AD mutation
Reduced LDL absorption = increased circulating LDL only
(Remains circulating for 5d rather than 2d!)
Heterozygosity > homozygosity
Arcus, xanthelasma, tendon xanthoma, pinpoint ostia

A

Familial hypercholesterolaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

3 types - I (LPL deficiency), III and IV (increased TG synthesis)
= Increased circulating TG only
Monogenic AD mutation
Type I = Milky plasma containing chylomicrons if left overnight
Types III / IV = Milky plasma containing VLDL if left overnight
Episodic abdo pain + recurrent pancreatitis
Eruptive xanthoma

A

Familial hypertriglyceridaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Mx familial hypertriglyceridaemia

A

Depends on cause:
Type I = reduce triglycerides (clearance problem)
Type III/IV = reduce carbohydrates (synthesis problem - reduce carbs to prevent conversion to TG!)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Effect of statins

A

Reduces LDL
Slight increase in HDL
Moderate reduction in TG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Novel LDL-lowering therapies

A

Mimics HDL - very effective at lowering LDL but causes fatty liver
Anti-PCSK9 monoclonal antibody - fortnightly injection, currently most promising